Childhood MenB vaccine to be introduced

According to JCVI, the Bexsero vaccine can effectively prevent infant MenB and should be used if it can be manufactured at a cost-effective price.

Professor Andrew Pollard, chairman of the Joint Committee on Vaccination and Immunisation (JCVI), said: "MenB disproportionately affects babies and young children and can be devastating. After very careful consideration, JCVI concluded that use of the new vaccine would reduce cases of meningococcal meningitis and septicaemia and lead to a reduction in deaths, limb amputations and brain injury caused by the disease.Today the JCVI published its recommendation to the UK health departments that if the new vaccine can be purchased at a low price and is therefore cost effective for the NHS, it should be used in the routine immunisation programme for babies in the UK to prevent disease.

"Routine use of the MenB vaccine is expected to make an important contribution to the health of our population."

READ MORE

Event Diary

This story was first published in digitalhealth.net

Supplier Profiles

CDC success at Victoria Infirmary, Northwich creates ideal model for future patient pathway reforms

Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients

Gain valuable insight with Adveco for gas to electric decarbonisation projects

Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho